glp 1 on insurance How many adults with private health could use GLP-1 drugs Insurance companies scrambling to support

E11.40 (Type 2, unspecified neuropathy), E11.41 (mononeuropathy), E11.42 (polyneuropathy, most common), E11.43 (autonomic neuropathy)

Pharmacokinetic Obstacles: The widespread clinical adoption of FOXO4-DRI is hindered by typical peptide-based limitations: rapid enzymatic degradation, low membrane permeability, and the requirement for injectable administration (PNAS, 2026)

FigueiredoJLAikawaMZhengCAaronJLaxLLibbyPet alSelective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease

Matsumura N, Kinoshita C, Bhadhprasit W, Nakaki T, Aoyama K (2023) A purine derivative, paraxanthine, promotes cysteine uptake for glutathione synthesis

Options may include low-dose prophylactic antibiotics, postcoital antibiotic prophylaxis for women with intercourse-related infections, or vaginal estrogen therapy for postmenopausal women